跳至主要内容
临床试验/NCT01380548
NCT01380548已完成不适用

A Double-blind, Placebo Controlled Study to Assess Efficacy of 5-Aminolevulinic Acid in Subjects With Iron Deficiency Anemia

Hiroshima University2 个研究点 分布在 1 个国家目标入组 135 人开始时间: 2011年6月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
135
试验地点
2
主要终点
Hemoglobin level

研究概览

简要总结

This study is designed to evaluate efficacy and dose-dependency of 5-aminolevulinic acid in subjects with iron deficiency anemia.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Double (Participant, Outcomes Assessor)

入排标准

年龄范围
20 Years 至 49 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Premenopausal women with hemoglobin ≥ 9.0 g/dl and ≤ 12.0 g/dl
  • Willing not to donate blood during the study
  • Informed consent signed

排除标准

  • History of porphyria, hemochromatosis, or viral hepatitis
  • Anemia other than iron deficiency
  • BMI ≤ 18 kg/m2 or ≥ 30 kg/m2
  • Pregnant or nursing a child
  • Participation in any clinical trial within 90 days of the commencement of the trial
  • Renal or hepatic dysfunction
  • Heart disease
  • Subjects who are taking medicines or functional food that may affect hemoglobin level

结局指标

主要结局

Hemoglobin level

时间窗: Every 4 weeks (Overall 20 weeks)

次要结局

  • Soluble transferrin receptor level(Week 0 (baseline) and Week 12)
  • Hepcidin-25 level(Week 0 (baseline) and Week 12)
  • Serum ferritin level(Every 4 weeks (Overall 20 weeks))
  • Transferrin level(Every 4 weeks (Overall 20 weeks))
  • MCV level(Every 4 weeks (Overall 20 weeks))
  • TIBC level(Every 4 weeks (Overall 20 weeks))
  • Reticulocyte level(Every 4 weeks (Overall 20 weeks))
  • Red blood cell level(Every 4 weeks (Overall 20 weeks))
  • Hematocrit level(Every 4 weeks (Overall 20 weeks))
  • Serum iron level(Every 4 weeks (Overall 20 weeks))

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Fumiko Higashikawa

Associate Professor

Hiroshima University

研究点 (2)

Loading locations...

相似试验